. 2019 Oct 8;22(3):475–486. doi: 10.1038/s41436-019-0667-y

Table 2.

Evidence map of study conclusions regarding the cost-effectiveness of PGx-guided testing

graphic file with name 41436_2019_667_Figa_HTML.gif

ACEl angiotensin-converting enzyme inhibitor, NOAC novel oral anticoagulant, PGx pharmacogenomics.

^aThe size of the pie chart reflects the number of studies captured, and the shaded area reflects the proportion of studies that reported PGx-guided treatments to be cost-effective. Cells that are empty suggest that no evidence was found for the drug from the corresponding perspective.

^bCoumarin derivatives, including phenprocoumon and acenocoumarol.

^cIncludes direct factor Xa inhibitors (apixaban, rivaroxaban, darexaban, edoxaban), direct thrombin inhibitors (dabigatran).